Skip to main content
OpenTrials
Completed

NCT Number: NCT00002175

Epicutaneous 1-Chloro-2, 4-Dinitrobenzene (DNCB) Patch in HIV Infection.

To evaluate the efficacy of dinitrochlorobenzene (DNCB) in patients with early HIV infection by monitoring immunologic parameters and serum HIV RNA. To facilitate the understanding of possible alterations in the immunological status of the HIV+ patient cohort.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV Infections Blood-Borne Infections Communicable Diseases Genital Diseases Immune System Diseases Immunologic Deficiency Syndromes Infections Lentivirus Infections RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Urogenital Diseases Virus Diseases

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Queen Emma Clinics / The Queen's Med Ctr

Honolulu, Hawaii, 96813, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients must have:

  • EITHER HIV negative or documented HIV+ by both the ELISA and Western blot tests.

For HIV+ patients:

  • Patients must fail to meet the AIDS-defining criteria.
  • CD4 lymphocyte count between 200 - 500 cells/mm3.

Exclusion criteria

Co-existing Condition:

Excluded:

Patients with obvious ultra violet(UV)-irradiated skin damage in the treatment sites.

Concurrent Medication:

Excluded:

  • Patients who are likely to commence antiretrovirals within the 6-month study period.
  • Patients using other immunomodulator therapies or other alternative therapies.
  • Patients likely to require chemotherapy during the course of the study.

Concurrent Treatment:

Excluded:

  • Patients who are likely to require significant UV light exposure during the study period.
  • Patients who are likely to require radiation therapy during the course of the study.

Prior Medication:

Excluded:

  • Prior exposure to DNCB.
  • Patients who have used antiretroviral medications within the previous 3 months.

Treatment and study plan

Dinitrochlorobenzene

Drug

Sponsors and collaborators

Lead sponsor

The Honolulu Medical Group

Other

Registry information

Important dates

First posted
Aug 31, 2001
Registry last updated
Jun 24, 2005

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.